@misc{indiciaef0ef6126ac0f,
  title = {Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).},
  author = {R Gervais and A Ducolone and J-L Breton and D Braun and B Lebeau and F Vaylet and D Debieuvre and J-L Pujol and J Tredaniel and P Clouet and E Quoix},
  year = {2005},
  doi = {10.1093/annonc/mdi018},
  url = {https://pubmed.ncbi.nlm.nih.gov/15598944/},
  note = {Source identifier: 15598944}
}